Dissociation of metabolic and hemodynamic levodopa responses in the 6-hydroxydopamine rat model

Neurobiology of Disease

Volumn 96, Issue , 2016, Pages 31-37

  Lerner, Renata P ^a   Bimpisidis, Zisis ^b   Agorastos, Stergiani ^a   Scherrer, Sandra ^a   Dewey, Stephen L ^a   Cenci, M Angela ^b   Eidelberg, David ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Cerebral blood flow; Glucose metabolism; Levodopa treatment; MicroPET; Parkinson's disease

Indexed keywords

BENSERAZIDE; DOPAMINE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; ISOFLURANE; KETAMINE; LEVODOPA; OXIDOPAMINE; WATER O 15; XYLAZINE; ADRENERGIC RECEPTOR BLOCKING AGENT; ANALGESIC AGENT; ANTIPARKINSON AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOMORPHINE TEST; ARTICLE; BASAL GANGLION; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN DAMAGE; BRAIN REGION; CEREBRAL METABOLIC RATE; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; DISSOCIATION; DRUG EFFECT; DRUG METABOLISM; DRUG RESPONSE; FEMALE; GLOBUS PALLIDUS; HEMODYNAMICS; IN VIVO STUDY; LEVODOPA-INDUCED DYSKINESIA; NERVOUS SYSTEM PARAMETERS; NEUROIMAGING; NONHUMAN; PET SCANNER; PRE-CLINICAL IMAGING DEVICE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; VASOMOTOR DISORDER; ANIMAL; BRAIN CIRCULATION; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PARKINSON DISEASE; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; SPRAGUE DAWLEY RAT;

ANALGESICS; ANIMALS; ANTIPARKINSON AGENTS; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; FEMALE; FLUORODEOXYGLUCOSE F18; HEMODYNAMICS; ISOFLURANE; KETAMINE; LEVODOPA; OXIDOPAMINE; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, SPRAGUE-DAWLEY; SYMPATHOLYTICS;

EID: 84983378556     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2016.08.010     Document Type: Article

References (25)

1. Afonso-Oramas, D., et al. Striatal vessels receive phosphorylated tyrosine hydroxylase-rich innervation from midbrain dopaminergic neurons. Front. Neuroanat., 8, 2014, 84.
2. Asanuma, K., et al. Network modulation in the treatment of Parkinson's disease. Brain 129 (2006), 2667–2678.
3. Cavazzuti, M., et al. Ketamine effects on local cerebral blood flow and metabolism in the rat. J. Cereb. Blood Flow Metab. 7 (1987), 806–811.
4. Cenci, M.A., Presynaptic mechanisms of L-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications. Front. Neurol., 5, 2014, 242.
5. Cenci, M.A., Lundblad, M., Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J. Neurochem. 99 (2006), 381–392.
6. Edvinsson, L., et al. Vasomotor response of cerebral blood vessels to dopamine and dopaminergic agonists. Adv. Neurol. 20 (1978), 85–96.
7. Edvinsson, L., et al. Vasomotor responses of cerebral arterioles in situ to putative dopamine receptor agonists. Br. J. Pharmacol. 85 (1985), 403–410.
8. Filosa, J.A., et al. Beyond neurovascular coupling, role of astrocytes in the regulation of vascular tone. Neuroscience 26 (2016), 96–109.
9. Garcia-Cabezas, M.A., et al. Distribution of the dopamine innervation in the macaque and human thalamus. NeuroImage 34 (2007), 965–984.
10. Guell, A., et al. Effects of a dopaminergic agonist (piribedil) on cerebral blood flow in man. J. Cereb. Blood Flow Metab. 2 (1982), 255–257.
11. Hirano, S., et al. Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease. J. Neurosci. 28 (2008), 4201–4209.
12. Jourdain, V.A., et al. Levodopa-induced changes in neurovascular reactivity in Parkinson's disease. Mov. Disord., 30, 2015, S11.
13. Leenders, K.L., et al. The effects of L-DOPA on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease. Brain 108:Pt 1 (1985), 171–191.
14. Lindgren, H.S., et al. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease. Neuropsychopharmacology 34 (2009), 2477–2488.
15. McCulloch, J., Edvinsson, L., Cerebral circulatory and metabolic effects of piribedil. Eur. J. Pharmacol. 66 (1980), 327–337.
16. Mosharov, E.V., et al. Presynaptic effects of levodopa and their possible role in dyskinesia. Mov. Disord. 30 (2015), 45–53.
17. Ohlin, K.E., et al. Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. Brain 134 (2011), 2339–2357.
18. Ohlin, K.E., et al. Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease. NeuroImage 61 (2012), 228–239.
19. Ruscher, K., et al. Levodopa treatment improves functional recovery after experimental stroke. Stroke 43 (2012), 507–513.
20. Schiffer, W.K., et al. Optimizing experimental protocols for quantitative behavioral imaging with 18F-FDG in rodents. J. Nucl. Med. 48 (2007), 277–287.
21. Smith, Y., Kieval, J.Z., Anatomy of the dopamine system in the basal ganglia. Trends Neurosci. 23 (2000), S28–S33.
22. Stanic, D., et al. Changes in function and ultrastructure of striatal dopaminergic terminals that regenerate following partial lesions of the SNpc. J. Neurochem. 86 (2003), 329–343.
23. Toda, N., Influence of dopamine and noradrenaline on isolated cerebral arteries of the dog. Br. J. Pharmacol. 58 (1976), 121–126.
24. Westin, J.E., et al. Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. J. Neurosci. 26 (2006), 9448–9461.
25. Winkler, C., et al. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 10 (2002), 165–186.